Loading news...
Game Creek Capital LP acquired a new stake in Novo Nordisk A/S (NYSE: NVO) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,250 shares of the company's stock, valued at approximately $1,290,000. A number of other hedge funds and
Investors are understandably fearful that Uber Technologies' profits are going to be under a growing degree of pressure. Insurer Progressive's outstanding 2025 results were too good to last.
Top insights from the latest market news from Friday, March 13, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Bank of Montreal Can cut its stake in shares of Novo Nordisk A/S (NYSE: NVO) by 57.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,057,418 shares of the company's stock after selling 1,417,882 shares during the period. Bank of Montreal Can's
Nine of the portfolio's 10 equity sectors made a positive impact on performance, with Health Care, Industrials, and Materials making the largest positive contributions. Palvella's shares appreciated significantly in 2025 as investors grew more confident in the company's pipeline following a grant from the FDA, patent wins, and a positive Phase II readout. Impinj is a long time holding in the portfolio with a very large total addressable market expansion opportunity, a strong patent portfolio, and an increasingly diversified customer base.
Novo Nordisk (NVO) closed the most recent trading day at $38.02, moving 2.09% from the previous trading session.
Top ten large cap value (GASV) stocks are forecasted to deliver an average 38.12% net gain by mid-March 2027, with yields up to 13.03%. Analyst targets suggest the five lowest-priced, highest-yield GASV stocks could outperform, offering an 18.5% higher gain than the top ten as a group. Fourteen of twenty-nine 'safer' lowest-priced GASV stocks are currently buyable, with seven meeting the ideal dividend-to-price criteria for fair value.
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate access to lucrative branded GLP-1 therapies. HIMS has demonstrated rapid revenue growth and improving profitability, with gross margins rising from 30% to nearly 75% and operating income turning positive. Valuation appears reasonable given future earnings growth potential, though current multiples are above sector averages on earnings but below on sales.
Not many things have gone right for Novo Nordisk recently, but this is one of them.
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims and Hers Health Inc (NYSE: HIMS) higher.
Novo Nordisk (NVO, Financials) has witnessed its share price plummet over the previous year, reducing the value of its largest shareholder's holdings.Novo Holdi
Capital International Sarl lessened its position in Novo Nordisk A/S (NYSE: NVO) by 80.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,563 shares of the company's stock after selling 35,881 shares during the period. Capital International Sarl's holdings in Novo Nordisk A/S
Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income from dividends from the Novo Group companies (DKK 15 billion or €2.0 billion) and Returns from the Investment Assets Portfolio 1 (DKK 5.8 billion or €0.8 billion).
India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promotions, as global and domestic drugmakers seek a share of the country's fast-growing obesity drug market.
The Novo Nordisk partnership legitimizes Hims & Hers' business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) with $318M EBITDA and $300M operating cash flow, demonstrating strong platform economics. The company ended 2025 with 2.5M+ subscribers and $83 average monthly revenue per user, reflecting growing cross-selling across health categories.
Hims & Hers (HIMS) is still a Strong Buy, given that the transformative partnership with Novo Nordisk resolves legal risks and unlocks new growth avenues. HIMS' core value lies in its 2.5M+ cash-pay customer base, enabling leverage with major pharma and supporting expansion into branded drug programs. With the Novo deal, I anticipate 2026 revenue could exceed $3.1B, sustaining 20%+ annual growth through 2029 and materially improving EBITDA margins.
NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.
US FDA hits Novo Nordisk with a "third strike" warning over "serious violations" in reporting Ozempic safety data, including deaths, strokes.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.